Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

By S. Schulman, C. Kearon, A. Kakkar, S. Schellong, H. Eriksson, David Baanstra, A. M. Kvamme, J. Friedman, P. Mismetti, Samuel Z. Goldhaber. New England Journal of Medicine, 2013

930 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology, Internal Medicine

View Paper: https://www.semanticscholar.org/paper/4a9bb527a78022c5781bfd2f6e46752fbbe5ef80

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. S. Schulman
2. G. Agnelli
3. Jeroen J. Bax
4. Jose Luis Zamorano
5. Alejandro Rabinstein
6. P. Lancellotti
7. R. Redberg
8. Nancy R. Cook

In Hematology

1. S. Konstantinides

In Internal Medicine

1. G. Agnelli
2. S. Konstantinides

Citations in the corpus

• Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “Direct thrombin inhibitors (DTI) are used for primary stroke prevention in patients with non-valvular atrial fibrillation [152], for treatment of deep venous thrombosis and pulmonary embolus [153, 154], and in the management of heparin-induced thrombocytopenia [155].”
• 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, methodology): “Dabigatran was compared with warfarin or placebo in two different studies (Supplementary Data Table 15).(350) In these studies, dabigatran was non-inferior to warfarin for the prevention of confirmed recurrent symptomatic VTE or VTE-related death, and more effective than placebo for the prevention o”
• Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. (2012, background): “ashx?url=/data/ (Table 7, e-Table 9).(47) Extended treatment with dabigatran,(47) rivaroxaban,(21) and apixaban(48) markedly reduces recurrent VTE without being associated with much bleeding (Tables 8-10, e-Tables 10-12).”
• ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014, methodology): “01 for non-inferiority).(370) The rate of major bleeding was 0.”
• [2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, neutral): “01 for non-inferiority).(370) The rate of major bleeding was 0.”
• American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. (2020, background): “Patients placed a high value on the benefits of risk reduction in VTE recurrence and PTS.(310) However, there is important variability in how individual patients may value the risk of thrombosis vs the risk of bleeding.”